Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01688960 | Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies | PHASE1 | COMPLETED | 48 | — | — | Oct 1, 2012 | Nov 1, 2014 | Mar 17, 2015 | 6 | United States, Canada |
| NCT01271972 | Study of Nesvacumab (REGN910/ SAR307746) | PHASE1 | COMPLETED | 53 | — | — | Jan 1, 2011 | May 1, 2015 | Jun 16, 2015 | 3 | United States, Canada |
Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) administered in combination with aflibercept (ziv-aflibercept) in patients with advanced solid malignancies
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3a | EXPERIMENTAL | - |
| Cohort 3b | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | Dose 3 |
| Cohort 5 | EXPERIMENTAL | Dose 5 |
| Expansion Cohort 1 | EXPERIMENTAL | Dose 4 |
| Expansion Cohort 2 | EXPERIMENTAL | Dose 5 |
| Name | Type | Description |
|---|---|---|
| nesvacumab (REGN910/ SAR307746) | DRUG | Dose level 1 |
| aflibercept (ziv-aflibercept) | DRUG | Dose level 1 |
Inclusion Criteria: Inclusion criteria include, but are not limited to, the following: 1. Confirmed diagnosis of solid tumor malignancy 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 3. Adequate hepatic, renal and bone marrow function 4. Resolution of toxicity from prior th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |